Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2013
For the nine months, the company's contract revenue was $3,045,000 against $5,894,000 a year ago. Loss from operations was $2,031,000 against $1,874,000 a year ago. Net loss was $2,541,000 or $0.03 per basic and diluted share against net income of $8,804,000 or $0.02 per diluted share a year ago. Net cash used in operating activities was $1,107,000 against $953,000 a year ago.